Cargando…
Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity
Trastuzumab (TZM) is useful in the clinical management of HER2-positive metastatic breast, gastric, and colorectal carcinoma but has been limited by its off-target cardiotoxicity. This study investigates the therapeutic potentials of 0.25 mg/kg/day amlodipine, 0.035 mg/kg/day lisinopril, 5 mg/kg/day...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058606/ https://www.ncbi.nlm.nih.gov/pubmed/33897413 http://dx.doi.org/10.3389/fphar.2020.610331 |
_version_ | 1783681046920822784 |
---|---|
author | Olorundare, Olufunke Esan Adeneye, Adejuwon Adewale Akinsola, Akinyele Olubiyi Ajayi, Abayomi Mayowa Agede, Olalekan Ayodele Soyemi, Sunday Sokunle Mgbehoma, Alban Ikenna Okoye, Ikechukwu Innocent Albrecht, Ralph M. Ntambi, James Mukasa Crooks, Peter Anthony |
author_facet | Olorundare, Olufunke Esan Adeneye, Adejuwon Adewale Akinsola, Akinyele Olubiyi Ajayi, Abayomi Mayowa Agede, Olalekan Ayodele Soyemi, Sunday Sokunle Mgbehoma, Alban Ikenna Okoye, Ikechukwu Innocent Albrecht, Ralph M. Ntambi, James Mukasa Crooks, Peter Anthony |
author_sort | Olorundare, Olufunke Esan |
collection | PubMed |
description | Trastuzumab (TZM) is useful in the clinical management of HER2-positive metastatic breast, gastric, and colorectal carcinoma but has been limited by its off-target cardiotoxicity. This study investigates the therapeutic potentials of 0.25 mg/kg/day amlodipine, 0.035 mg/kg/day lisinopril, 5 mg/kg/day valsartan, and their fixed-dose combinations in TZM-intoxicated Wistar rats that were randomly allotted into 10 groups of 6 rats for each group. Group I rats were treated with 10 ml/kg/day sterile water orally and 1 ml/kg/day sterile water intraperitoneally; Groups II, III, and IV rats were orally gavaged with 5 mg/kg/day valsartan and 1 ml/kg/day sterile water intraperitoneally, 0.25 mg/kg/day amlodipine and 1 ml/kg/day sterile water via the intraperitoneal route, 0.035 mg/kg/day lisinopril and 1 ml/kg/day sterile water administered intraperitoneally, respectively. Group V rats were orally treated with 10 ml/kg/day of sterile water prior to intraperitoneal administration of 2.25 mg/kg/day of TZM. Groups VI–VIII rats were equally pretreated with 5 mg/kg/day valsartan, 0.25 mg/kg/day amlodipine, and 0.035 mg/kg/day lisinopril before intraperitoneal 2.25 mg/kg/day TZM treatment, respectively; Groups IX and X rats were orally pretreated with the fixed-dose combinations of 0.25 mg/kg/day amlodipine +0.035 mg/kg/day lisinopril and 5 mg/kg/day valsartan +0.035 mg/kg/day lisinopril, respectively, before TZM treatment. Cardiac injury and tissue oxidative stress markers, complete lipids profile, histopathological, and immunohistochemical assays were the evaluating endpoints. Results showed that repeated TZM treatments caused profound increases in the serum TG and VLDL-c levels, serum cTnI and LDH levels, and cardiac tissue caspase-3 and -9 levels but decreased BCL-2 expression. TZM also profoundly attenuated CAT, SOD, GST and GPx activities, and increased MDA levels in the treated tissues. In addition, TZM cardiotoxicity was characterized by marked vascular and cardiomyocyte congestion and coronary artery microthrombi formation. However, the altered biochemical, histopathological, and immunohistochemical changes were reversed with amlodipine, lisinopril, valsartan, and fixed-dose combinations, although fixed-dose valsartan/lisinopril combination was further associated with hyperlipidemia and increased AI and CRI values and coronary artery cartilaginous metaplasia. Thus, the promising therapeutic potentials of amlodipine, lisinopril, valsartan and their fixed-dose combinations in the management of TZM cardiotoxicity, majorly mediated via antiapoptotic and oxidative stress inhibition mechanisms were unveiled through this study. |
format | Online Article Text |
id | pubmed-8058606 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80586062021-04-22 Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity Olorundare, Olufunke Esan Adeneye, Adejuwon Adewale Akinsola, Akinyele Olubiyi Ajayi, Abayomi Mayowa Agede, Olalekan Ayodele Soyemi, Sunday Sokunle Mgbehoma, Alban Ikenna Okoye, Ikechukwu Innocent Albrecht, Ralph M. Ntambi, James Mukasa Crooks, Peter Anthony Front Pharmacol Pharmacology Trastuzumab (TZM) is useful in the clinical management of HER2-positive metastatic breast, gastric, and colorectal carcinoma but has been limited by its off-target cardiotoxicity. This study investigates the therapeutic potentials of 0.25 mg/kg/day amlodipine, 0.035 mg/kg/day lisinopril, 5 mg/kg/day valsartan, and their fixed-dose combinations in TZM-intoxicated Wistar rats that were randomly allotted into 10 groups of 6 rats for each group. Group I rats were treated with 10 ml/kg/day sterile water orally and 1 ml/kg/day sterile water intraperitoneally; Groups II, III, and IV rats were orally gavaged with 5 mg/kg/day valsartan and 1 ml/kg/day sterile water intraperitoneally, 0.25 mg/kg/day amlodipine and 1 ml/kg/day sterile water via the intraperitoneal route, 0.035 mg/kg/day lisinopril and 1 ml/kg/day sterile water administered intraperitoneally, respectively. Group V rats were orally treated with 10 ml/kg/day of sterile water prior to intraperitoneal administration of 2.25 mg/kg/day of TZM. Groups VI–VIII rats were equally pretreated with 5 mg/kg/day valsartan, 0.25 mg/kg/day amlodipine, and 0.035 mg/kg/day lisinopril before intraperitoneal 2.25 mg/kg/day TZM treatment, respectively; Groups IX and X rats were orally pretreated with the fixed-dose combinations of 0.25 mg/kg/day amlodipine +0.035 mg/kg/day lisinopril and 5 mg/kg/day valsartan +0.035 mg/kg/day lisinopril, respectively, before TZM treatment. Cardiac injury and tissue oxidative stress markers, complete lipids profile, histopathological, and immunohistochemical assays were the evaluating endpoints. Results showed that repeated TZM treatments caused profound increases in the serum TG and VLDL-c levels, serum cTnI and LDH levels, and cardiac tissue caspase-3 and -9 levels but decreased BCL-2 expression. TZM also profoundly attenuated CAT, SOD, GST and GPx activities, and increased MDA levels in the treated tissues. In addition, TZM cardiotoxicity was characterized by marked vascular and cardiomyocyte congestion and coronary artery microthrombi formation. However, the altered biochemical, histopathological, and immunohistochemical changes were reversed with amlodipine, lisinopril, valsartan, and fixed-dose combinations, although fixed-dose valsartan/lisinopril combination was further associated with hyperlipidemia and increased AI and CRI values and coronary artery cartilaginous metaplasia. Thus, the promising therapeutic potentials of amlodipine, lisinopril, valsartan and their fixed-dose combinations in the management of TZM cardiotoxicity, majorly mediated via antiapoptotic and oxidative stress inhibition mechanisms were unveiled through this study. Frontiers Media S.A. 2021-03-04 /pmc/articles/PMC8058606/ /pubmed/33897413 http://dx.doi.org/10.3389/fphar.2020.610331 Text en Copyright © 2021 Olorundare, Adeneye, Akinsola, Ajayi, Agede, Soyemi, Mgbehoma, Okoye, Albrecht, Ntambi and Crooks. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Olorundare, Olufunke Esan Adeneye, Adejuwon Adewale Akinsola, Akinyele Olubiyi Ajayi, Abayomi Mayowa Agede, Olalekan Ayodele Soyemi, Sunday Sokunle Mgbehoma, Alban Ikenna Okoye, Ikechukwu Innocent Albrecht, Ralph M. Ntambi, James Mukasa Crooks, Peter Anthony Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity |
title | Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity |
title_full | Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity |
title_fullStr | Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity |
title_full_unstemmed | Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity |
title_short | Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity |
title_sort | therapeutic potentials of selected antihypertensive agents and their fixed-dose combinations against trastuzumab-mediated cardiotoxicity |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058606/ https://www.ncbi.nlm.nih.gov/pubmed/33897413 http://dx.doi.org/10.3389/fphar.2020.610331 |
work_keys_str_mv | AT olorundareolufunkeesan therapeuticpotentialsofselectedantihypertensiveagentsandtheirfixeddosecombinationsagainsttrastuzumabmediatedcardiotoxicity AT adeneyeadejuwonadewale therapeuticpotentialsofselectedantihypertensiveagentsandtheirfixeddosecombinationsagainsttrastuzumabmediatedcardiotoxicity AT akinsolaakinyeleolubiyi therapeuticpotentialsofselectedantihypertensiveagentsandtheirfixeddosecombinationsagainsttrastuzumabmediatedcardiotoxicity AT ajayiabayomimayowa therapeuticpotentialsofselectedantihypertensiveagentsandtheirfixeddosecombinationsagainsttrastuzumabmediatedcardiotoxicity AT agedeolalekanayodele therapeuticpotentialsofselectedantihypertensiveagentsandtheirfixeddosecombinationsagainsttrastuzumabmediatedcardiotoxicity AT soyemisundaysokunle therapeuticpotentialsofselectedantihypertensiveagentsandtheirfixeddosecombinationsagainsttrastuzumabmediatedcardiotoxicity AT mgbehomaalbanikenna therapeuticpotentialsofselectedantihypertensiveagentsandtheirfixeddosecombinationsagainsttrastuzumabmediatedcardiotoxicity AT okoyeikechukwuinnocent therapeuticpotentialsofselectedantihypertensiveagentsandtheirfixeddosecombinationsagainsttrastuzumabmediatedcardiotoxicity AT albrechtralphm therapeuticpotentialsofselectedantihypertensiveagentsandtheirfixeddosecombinationsagainsttrastuzumabmediatedcardiotoxicity AT ntambijamesmukasa therapeuticpotentialsofselectedantihypertensiveagentsandtheirfixeddosecombinationsagainsttrastuzumabmediatedcardiotoxicity AT crookspeteranthony therapeuticpotentialsofselectedantihypertensiveagentsandtheirfixeddosecombinationsagainsttrastuzumabmediatedcardiotoxicity |